{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=adjuvanted+influenza+vaccine",
    "query": {
      "intervention": "adjuvanted influenza vaccine"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 79,
    "total_pages": 8,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=adjuvanted+influenza+vaccine&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-10-10T11:55:02.015Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02151344",
      "title": "Evaluating the Safety and Immune Response to a Live H7N9 Influenza Virus Vaccine Followed by an Inactivated H7N9 Influenza Virus Vaccine, Given at Varying Intervals",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Influenza A Virus, H7N9 Subtype"
      ],
      "interventions": [
        {
          "name": "H7N9 A/Anhui/13 ca influenza virus vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Inactivated subvirion H7N9 vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 100,
      "start_date": "2014-05",
      "completion_date": "2015-02",
      "has_results": false,
      "last_update_posted_date": "2015-03-30",
      "last_synced_at": "2026-10-10T11:55:02.015Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02151344"
    },
    {
      "nct_id": "NCT00662272",
      "title": "Safety and Efficacy Study of Fluzone® Vaccine Combined With Different Doses of JVRS-100 Adjuvant",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "Fluzone vaccine with JVRS-100 adjuvant",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Fluzone vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Colby Pharmaceutical Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 128,
      "start_date": "2008-06",
      "completion_date": "2009-12",
      "has_results": false,
      "last_update_posted_date": "2010-03-17",
      "last_synced_at": "2026-10-10T11:55:02.015Z",
      "location_count": 2,
      "location_summary": "Miami, Florida • Lenexa, Kansas",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Lenexa",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00662272"
    },
    {
      "nct_id": "NCT01623232",
      "title": "MAS-1 Adjuvanted Compared to Unadjuvanted Influenza Vaccines in the Elderly",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Influenza Vaccines",
        "Aged"
      ],
      "interventions": [
        {
          "name": "MAS-1 adjuvant and influenza HA antigen",
          "type": "BIOLOGICAL"
        },
        {
          "name": "standard dose, inactivated trivalent influenza vaccine (TIV)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "US Department of Veterans Affairs",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "65 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2012-10",
      "completion_date": "2014-06",
      "has_results": false,
      "last_update_posted_date": "2012-09-26",
      "last_synced_at": "2026-10-10T11:55:02.015Z",
      "location_count": 4,
      "location_summary": "Palo Alto, California • Iowa City, Iowa • Minneapolis, Minnesota + 1 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01623232"
    },
    {
      "nct_id": "NCT06695117",
      "title": "Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and High-Dose Inactivated Influenza Vaccine in Adult Participants 50 Years of Age and Older",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "COVID-19 Immunization",
        "Influenza Immunization"
      ],
      "interventions": [
        {
          "name": "IIV-HD",
          "type": "BIOLOGICAL"
        },
        {
          "name": "rC19 (dose 1)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "IIV-HD + rC19 (dose 1)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "IIV-HD + rC19 (dose 2)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "IIV-HD + rC19 (dose 3)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "IIV-HD + rC19 (dose 4)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo (0.9% NaCl)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 980,
      "start_date": "2024-11-19",
      "completion_date": "2026-04-16",
      "has_results": false,
      "last_update_posted_date": "2026-05-05",
      "last_synced_at": "2026-10-10T11:55:02.015Z",
      "location_count": 12,
      "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Tucson, Arizona + 9 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "The Villages",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06695117"
    },
    {
      "nct_id": "NCT05007041",
      "title": "Simultaneous RZV and aIIV4 Vaccination",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Pain",
        "Quality of Life",
        "Injection Site Reaction",
        "Adverse Drug Event"
      ],
      "interventions": [
        {
          "name": "FLUAD® Quadrivalent",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Fluzone® High-Dose Quadrivalent",
          "type": "BIOLOGICAL"
        },
        {
          "name": "SHINGRIX®",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "65 Years and older"
      },
      "enrollment_count": 267,
      "start_date": "2021-09-21",
      "completion_date": "2023-06-08",
      "has_results": true,
      "last_update_posted_date": "2024-07-11",
      "last_synced_at": "2026-10-10T11:55:02.015Z",
      "location_count": 2,
      "location_summary": "Baltimore, Maryland • Durham, North Carolina",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05007041"
    },
    {
      "nct_id": "NCT01910519",
      "title": "Systems Biology of Influenza A (H5N1) Virus Monovalent Vaccine With and Without Adjuvant System 03 (AS03)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Influenza A Virus, H5N1 Subtype"
      ],
      "interventions": [
        {
          "name": "H5N1 vaccine plus AS03 adjuvant",
          "type": "BIOLOGICAL"
        },
        {
          "name": "H5N1 vaccine without adjuvant",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "21 Years to 45 Years"
      },
      "enrollment_count": 50,
      "start_date": "2013-07",
      "completion_date": "2015-11",
      "has_results": true,
      "last_update_posted_date": "2019-02-12",
      "last_synced_at": "2026-10-10T11:55:02.015Z",
      "location_count": 1,
      "location_summary": "Decatur, Georgia",
      "locations": [
        {
          "city": "Decatur",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01910519"
    },
    {
      "nct_id": "NCT01320696",
      "title": "Reverse Genetic H9N2 Influenza Vaccine Study in Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "Reverse Genetic (RG) reassortant A/H9N2 influenza vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Alachua Government Services, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 353,
      "start_date": "2011-03",
      "completion_date": "2012-05",
      "has_results": true,
      "last_update_posted_date": "2023-02-16",
      "last_synced_at": "2026-10-10T11:55:02.015Z",
      "location_count": 5,
      "location_summary": "Huntsville, Alabama • Melbourne, Florida • Peoria, Illinois + 2 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Melbourne",
          "state": "Florida"
        },
        {
          "city": "Peoria",
          "state": "Illinois"
        },
        {
          "city": "South Bend",
          "state": "Indiana"
        },
        {
          "city": "Rockville",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01320696"
    },
    {
      "nct_id": "NCT01310413",
      "title": "Monovalent H5N1 Vaccine GSK1557484A in Children 6 Months to < 18 Years of Age",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Influenza",
        "Influenza Vaccines"
      ],
      "interventions": [
        {
          "name": "Influenza A (H5N1) Virus monovalent vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Saline placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "6 Months to 17 Years"
      },
      "enrollment_count": 842,
      "start_date": "2011-03-07",
      "completion_date": "2014-01-26",
      "has_results": true,
      "last_update_posted_date": "2021-11-01",
      "last_synced_at": "2026-10-10T11:55:02.015Z",
      "location_count": 11,
      "location_summary": "Paramount, California • Sacramento, California • Newton, Kansas + 8 more",
      "locations": [
        {
          "city": "Paramount",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Newton",
          "state": "Kansas"
        },
        {
          "city": "Bardstown",
          "state": "Kentucky"
        },
        {
          "city": "Metairie",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01310413"
    },
    {
      "nct_id": "NCT02957656",
      "title": "Safety and Immunogenicity of Priming With Live Attenuated A/H7N9 Influenza Virus Vaccine Followed By Inactivated A/H7N9 Influenza Virus Vaccine With AS03 Adjuvant",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Influenza A Virus, H7N9 Subtype"
      ],
      "interventions": [
        {
          "name": "H7N9 pLAIV",
          "type": "BIOLOGICAL"
        },
        {
          "name": "H7N9 pIIV",
          "type": "BIOLOGICAL"
        },
        {
          "name": "AS03 adjuvant",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "20 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "20 Years to 49 Years"
      },
      "enrollment_count": 53,
      "start_date": "2016-12",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2018-10-02",
      "last_synced_at": "2026-10-10T11:55:02.015Z",
      "location_count": 1,
      "location_summary": "Rochester, New York",
      "locations": [
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02957656"
    },
    {
      "nct_id": "NCT00812019",
      "title": "Dose Ranging Study to Evaluate Immunogenicity and Safety of Adjuvanted or Non-adjuvanted Cell Culture-derived H5N1 Influenza Vaccine in Young Adults (18-40 Years Old)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 3.75_0%MF59",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 3.75_25%MF59",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 3.75_50%MF59",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 3.75_100%MF59",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 7.5_0%MF59",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 7.5_25%MF59",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 7.5_50%MF59",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 7.5_100%MF59",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 15_0%MF59",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 15_25%MF59",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 15_50%MF59",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 15_100%MF59",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Seqirus",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "18 Years to 40 Years"
      },
      "enrollment_count": 753,
      "start_date": "2008-11",
      "completion_date": "2010-11",
      "has_results": false,
      "last_update_posted_date": "2020-08-24",
      "last_synced_at": "2026-10-10T11:55:02.015Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00812019"
    }
  ]
}